Clene Inc. (CLNN) company profile
Close on Nov 17, 2026Market cap $41.37MP/E –Yield –
About Clene
Pharmaceutical Preparations, SIC 2834
This clinical-stage pharmaceutical company develops clean-surfaced nanotechnology therapeutics designed to treat neurodegenerative diseases and central nervous system disorders, including amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease. Its proprietary platform synthesizes stable, highly catalytic nanocrystals from transition elements without toxic organic residues. The company's lead drug asset is an orally administered gold nanocrystal suspension engineered to restore cellular energy metabolism, increase intracellular adenosine triphosphate production, and reduce oxidative stress and toxic protein aggregates. Additional pipeline candidates in early development include ionic solutions for infectious diseases and wound healing. It also markets mineral dietary supplements, either directly through a subsidiary or via licensing partnerships with supplement distributors.
The company operates its clinical research programs across various healthcare centers within the United States and has conducted long-term clinical trial extensions in Australia. In addition to its clinical pipeline, the company distributes commercial dietary supplements internationally through a licensing partner. The company's corporate headquarters and executive offices are not stated in the provided text.
Summary of the business section of Clene's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Clene Inc.
- Headquarters
- Salt Lake City, UT
- Address
- 6550 South Millrock Drive, Suite G50 84121
- Phone
- (801) 676-9695
- Website
- clene.com
- Employees
- 79, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Salt Lake City, Utah
Stock & identifiers
- Ticker
- CLNN
- Exchange
- Nasdaq
- IPO date
- Oct 18, 2018
- Shares outstanding
- 13M, Aug 11, 2026
- Public float
- $40.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Jul 11, 2024
- SEC CIK
- 1822791
- CUSIP
- 185634201
- ISIN
- US1856342019
- FIGI
- BBG00X3GTK66
- Share class FIGI
- BBG00X3GTK84
- EIN
- 85-2828339
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert Dee Etherington | President & CEO, Director | 57,279 |
| Mark Mortenson | Chief Science Officer | 28,949 |
| Morgan R. Brown | Chief Financial Officer | 0 |
| Alison Mosca | Director | 703,974 |
| Arjun JJ Desai | Director | 16,298 |
| Vallerie McLaughlin | Director | – |
| Reed N. Wilcox | Director | 575,145 |
| Matthew Kiernan | Director | 8,540 |
| Jonathon Gay | Director | 2,329,218 |
| Shalom Jacobovitz | Director | 20,838 |
| David J. Matlin | Director | 919,775 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Robert Etherington President and Chief Executive Officer | $508.76K | $386.15K | $38.48K | $933.39K | -32% |
| Mark Mortenson Chief Science Officer | $412.02K | $368.36K | $29.05K | $809.43K | -25% |
| Morgan R. Brown Chief Financial Officer | $292.58K | $163.49K | $31.59K | $487.65K | -36% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 79 employees, 76 of which were full-time and 3 were part-time, primarily located in Utah and Maryland.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?